Axalimogene filolisbac is under clinical development by Advaxis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Axalimogene filolisbac’s likelihood of approval (LoA) and phase transition for Oropharyngeal Cancer took place on 23 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Axalimogene filolisbac Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Axalimogene filolisbac overview

Axalimogene filolisbac (ADXS-HPV, ADXS11-001, human papillomavirus (HPV) vaccine) is under development for the treatment of cervical squamous cell carcinoma, rectal cancer, HPV-Positive oropharyngeal squamous cell carcinoma and non-squamous, HPV associated cancers such as head and neck squamous cell carcinoma and cervical cancer in combination with durvalumab. The vaccine candidate is administered intravenously. It is a live attenuated Listeria cancer vaccine which specifically contains HPV-16-E7 antigen specific for cervical carcinoma. It is based on Listeria technology platform which uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. It was under development for the treatment of anal cancer and  HPV associated cancers such as non-small cell lung carcinoma.

Advaxis overview

Advaxis is a biotechnology company that focuses on the discovery, development, and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology, an antigen delivery platform that activates the immune system naturally. The Lm technology uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen. Its immunotherapy candidates are intended for the treatment of neoantigen-directed therapies, prostate cancer, and human papilloma virus-associated cancers. The company has partnerships with various biopharmaceutical companies to develop and commercialize proprietary cancer immunotherapies. Advaxis is headquartered in Princeton, New Jersey, the US.

Quick View Axalimogene filolisbac LOA Data

Report Segments
  • Innovator
Drug Name
  • Axalimogene filolisbac
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.